Not Yet Recruiting
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer - CA209-6L6
Mis à jour:
22 mars, 2023
|
ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Not Yet Recruiting
Inclusion Criteria: - Participant must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. - Participants must be eligible for adjuvant therapy for melanoma or muscle-invasive Urothelial Carcinoma (UC) originating from the bladder. - All participants must have disease-free status (DFS) documented by a complete physical examination and imaging studies within 4 weeks prior to treatment assignment. Exclusion Criteria: - History of ocular or uveal or mucosal melanoma. - Upper tract UC (ureter, renal pelvis), non-muscle-invasive UC. - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment. - Untreated/unresected Central Nervous System (CNS) or leptomeningeal metastases. Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales